Matches in SemOpenAlex for { <https://semopenalex.org/work/W2736335461> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2736335461 abstract "OBJECTIVE: To evaluate the efficacy and safety of lacosamide in institutionalized mentally retarded and refractory epileptic patients. BACKGROUND: Despite the introduction of multiple new antiepileptic drugs (AEDs) in the past 20 years, about 30% of patients with epilepsy continue to experience uncontrolled seizures or significant side effects. This resistance to treatment is even higher in people with mental retardation. In fact, the experience of AEDS in this kind of patients is very low and none of them has been proposed as a good therapeutic option. DESIGN/METHODS: This is a retrospective study and we reviewed the medical charts of all institutionalized mentally retarded and refractory epileptic patients receiving oral lacosamide until October 2012. These patients were classified according the severity of their mental retardation: mild, moderate and severe. Efficacy was determined according the seizure frequency during the month prior to treatment initiation and the month after the maximal dosage. RESULTS: Forty six patients (20 men and 26 women) aged 18-66 (mean 27.9±11.0) years were enrolled. Twenty two suffered perinatal anoxia, ten had epilepsy attributed to a structural cause, nine had epilepsy of unknown cause, and five had Lennox-Gastaut syndrome. The mean number of AEDs they were taking was 2.6±0.7 and the previous AEDs they had tried were 6.8±2.0. The mean follow-up was 4.6±2.4 months. Fifteen (33%) patients had at least a 50% seizure reduction, while a small decrease was obtained in another fifteen (33%). It was discontinued in six (13%) patients because of inefficacy. Side effects were reported in seven (15%) patients. These results were similar in all subgroups. CONCLUSIONS: Lacosamide seems to be effective and safe in mentally retarded and refractory epileptic patients according to our cohort and these results are independent of the degree of mental retardation of the patients. According to our results, lacosamide could be an important option for these patients. Supported by: UCB. Disclosure: Dr. Bermejo has received research support from UCB. Dr. Bermejo has received research support from UCB." @default.
- W2736335461 created "2017-07-31" @default.
- W2736335461 creator A5036238924 @default.
- W2736335461 creator A5055139784 @default.
- W2736335461 date "2013-02-12" @default.
- W2736335461 modified "2023-09-23" @default.
- W2736335461 title "Lacosamide Use in Institutionalized Mentally Retarded and Refractory Epileptic Patients (P01.041)" @default.
- W2736335461 hasPublicationYear "2013" @default.
- W2736335461 type Work @default.
- W2736335461 sameAs 2736335461 @default.
- W2736335461 citedByCount "0" @default.
- W2736335461 crossrefType "journal-article" @default.
- W2736335461 hasAuthorship W2736335461A5036238924 @default.
- W2736335461 hasAuthorship W2736335461A5055139784 @default.
- W2736335461 hasConcept C118552586 @default.
- W2736335461 hasConcept C121332964 @default.
- W2736335461 hasConcept C126322002 @default.
- W2736335461 hasConcept C138496976 @default.
- W2736335461 hasConcept C142424586 @default.
- W2736335461 hasConcept C15744967 @default.
- W2736335461 hasConcept C167135981 @default.
- W2736335461 hasConcept C187212893 @default.
- W2736335461 hasConcept C195910791 @default.
- W2736335461 hasConcept C2778139780 @default.
- W2736335461 hasConcept C2778186239 @default.
- W2736335461 hasConcept C3019965780 @default.
- W2736335461 hasConcept C71924100 @default.
- W2736335461 hasConcept C87355193 @default.
- W2736335461 hasConceptScore W2736335461C118552586 @default.
- W2736335461 hasConceptScore W2736335461C121332964 @default.
- W2736335461 hasConceptScore W2736335461C126322002 @default.
- W2736335461 hasConceptScore W2736335461C138496976 @default.
- W2736335461 hasConceptScore W2736335461C142424586 @default.
- W2736335461 hasConceptScore W2736335461C15744967 @default.
- W2736335461 hasConceptScore W2736335461C167135981 @default.
- W2736335461 hasConceptScore W2736335461C187212893 @default.
- W2736335461 hasConceptScore W2736335461C195910791 @default.
- W2736335461 hasConceptScore W2736335461C2778139780 @default.
- W2736335461 hasConceptScore W2736335461C2778186239 @default.
- W2736335461 hasConceptScore W2736335461C3019965780 @default.
- W2736335461 hasConceptScore W2736335461C71924100 @default.
- W2736335461 hasConceptScore W2736335461C87355193 @default.
- W2736335461 hasOpenAccess W2736335461 @default.
- W2736335461 hasRelatedWork W1481585431 @default.
- W2736335461 hasRelatedWork W172837553 @default.
- W2736335461 hasRelatedWork W1953623782 @default.
- W2736335461 hasRelatedWork W1976211506 @default.
- W2736335461 hasRelatedWork W2038011944 @default.
- W2736335461 hasRelatedWork W2060121528 @default.
- W2736335461 hasRelatedWork W2077605613 @default.
- W2736335461 hasRelatedWork W2128527749 @default.
- W2736335461 hasRelatedWork W2167720018 @default.
- W2736335461 hasRelatedWork W2341866581 @default.
- W2736335461 hasRelatedWork W2470130418 @default.
- W2736335461 hasRelatedWork W2552636290 @default.
- W2736335461 hasRelatedWork W2564950111 @default.
- W2736335461 hasRelatedWork W2912177640 @default.
- W2736335461 hasRelatedWork W3007846448 @default.
- W2736335461 hasRelatedWork W3036431220 @default.
- W2736335461 hasRelatedWork W3089252390 @default.
- W2736335461 hasRelatedWork W1913083181 @default.
- W2736335461 hasRelatedWork W2183118072 @default.
- W2736335461 hasRelatedWork W2492215781 @default.
- W2736335461 hasVolume "80" @default.
- W2736335461 isParatext "false" @default.
- W2736335461 isRetracted "false" @default.
- W2736335461 magId "2736335461" @default.
- W2736335461 workType "article" @default.